Aptiganel

CAS No. 137159-92-3

Aptiganel( —— )

Catalog No. M34164 CAS No. 137159-92-3

Aptiganel (CNS-1102) is a non-competitive NMDA antagonist, a peptide that may be used to study acute ischemic stroke.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Aptiganel
  • Note
    Research use only, not for human use.
  • Brief Description
    Aptiganel (CNS-1102) is a non-competitive NMDA antagonist, a peptide that may be used to study acute ischemic stroke.
  • Description
    Aptiganel (CNS 1102 (free base)), peptide, is a noncompetitive NMDA antagonist with cerebroprotective effects. Aptiganel can be used for the research of stroke.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    NMDAR
  • Recptor
    NMDAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    137159-92-3
  • Formula Weight
    303.4
  • Molecular Formula
    C20H21N3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N=C(NC1=CC=CC=2C=CC=CC21)N(C3=CC=CC(=C3)CC)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Meadows ME, et al. Delayed treatment with a non-competitive NMDA antagonist, CNS-1102 reduces infarct size in rats. Cerebrovasc Dis.1994;4:26-31.
molnova catalog
related products
  • (R)-Serine

    (R)-Serine is an endogenous amino acidis a potent co-agonist at the NMDA glutamate receptor.

  • MRZ 2-514

    MRZ 2-514 is a strychnine-insensitive modulatory site of the NMDA receptor (glycineB)antagonist with Ki of 33 μM.

  • Glabridin

    Glabridin may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction, through regulating the synthesis and activity of iNOS under high-glucose levels.